


Amended Claims (Attorney Docket No. LeA 35 926)


1. (Original) A compound of the formula



in which

R^1 is $C_6\text{-}C_{10}$ -aryl or 5- to 10-membered heteroaryl which are optionally substituted by radicals selected from the group of halogen, cyano, $C_1\text{-}C_6$ -alkoxy, $C_1\text{-}C_6$ -alkoxycarbonyl, trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, $C_1\text{-}C_4$ -alkyl and $C_3\text{-}C_8$ -cycloalkyl, where $C_1\text{-}C_4$ -alkyl is optionally substituted by hydroxy,

or a group of the formula



or

4- to 12-membered heterocyclyl which is bonded via a nitrogen atom and which is optionally substituted by radicals selected from the group of $-\text{NHR}^2$, halogen, $C_1\text{-}C_6$ -alkoxycarbonyl, $C_1\text{-}C_6$ -alkoxy, $C_1\text{-}C_6$ -alkyl and oxo, where $C_1\text{-}C_6$ -alkyl is optionally substituted by hydroxy, and

R^2 is $C_1\text{-}C_4$ -alkyl,

or


$C_4\text{-}C_8$ -cycloalkyl which is substituted in the position adjacent to the point of attachment by oxo, and which is optionally substituted by $C_1\text{-}C_4$ -alkyl,

and the salts, solvates and/or solvates of the salts thereof.

2. (Original) The compound as claimed in claim 1, where

R¹ is phenyl or 5- to 6-membered heteroaryl, which are optionally substituted by radicals selected from the group of fluorine, chlorine, cyano, C₁-C₃-alkoxycarbonyl, C₁-C₃-alkoxy, trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, C₁-C₃-alkyl and C₃-C₅-cycloalkyl, where C₁-C₃-alkyl is optionally substituted by hydroxy,

or a group of the formula



or

4- to 12-membered heterocyclyl which is bonded via a nitrogen atom and which is optionally substituted by radicals selected from the group of -NHR², fluorine, chlorine, C₁-C₃-alkyl, C₁-C₃-alkoxycarbonyl, C₁-C₃-alkoxy and oxo, where C₁-C₃-alkyl is optionally substituted by hydroxy,

and

R² is C₁-C₃-alkyl,

or


cyclohexyl which is substituted in the position adjacent to the point of attachment by oxo, and which is optionally substituted by C₁-C₂-alkyl,

and the salts, solvates and/or solvates of the salts thereof.

3. (Original) The compound as claimed in claim 1 or 2, where

R¹ is phenyl or pyridyl, pyrazolyl, isoxazolyl, which are optionally substituted by radicals selected from the group of fluorine, chlorine, cyano, methoxy, methoxycarbonyl, ethoxycarbonyl, trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, methyl, cyclopropyl or hydroxymethyl,

or a group of the formula



or

4- to 12-membered heterocycl^l which is bonded via a nitrogen atom and which is optionally substituted by radicals selected from the group of $-NHR^2$, fluorine, chlorine, C₁-C₃-alkyl, methoxy, ethoxy, hydroxymethyl and oxo, and

R² is methyl,


or

cyclohexyl which is substituted in the position adjacent to the point of attachment by oxo, and which is optionally substituted by methyl,

and the salts, solvates and/or solvates of the salts thereof.

4. (Currently amended) A process for preparing compounds of the formula (IV), (VI) and (VII), characterized in that either

[A] compounds of the formula




in which X is chlorine, bromine, iodine, preferably bromine,

are reacted with a compound of the formula

$R^3\text{-NH-}R^4$ (III),


in which

R^3, R^4 together with the nitrogen atom to which they are bonded are a 4- to 12-membered heterocyclyl which is optionally substituted by radicals selected from the group of – NHR^2 , halogen, $C_1\text{-}C_6$ -alkoxycarbonyl, $C_1\text{-}C_6$ -alkoxy, $C_1\text{-}C_6$ -alkyl and oxo, where $C_1\text{-}C_6$ -alkyl is optionally substituted by $-\text{OR}^5$, and R^2 has the meaning indicated in claim 1 above, R^5 is a hydroxy protective group in an inert solvent in the presence of a base and of a transition metal catalyst to give compounds of the formula




or

[B] compounds of the formula (II) are reacted with a compound of the formula




in which

R^6 is cycloalkyl, R^7 is hydrogen or R^6 and R^7 together with the CH_2CO group to which they are bonded are cycloalkyl which may be substituted by $C_1\text{-}C_6$ -alkyl radicals, in an inert solvent in the presence of a base and of a transition metal catalyst to give compounds of the formula



or

[C] compounds of the formula (II) are reacted with a compound of the formula



in which


A is $-B(OR^9)_2$ or $-Sn(C_1\text{-}C_6\text{-alkyl})_3$, where

R^9 is hydrogen, $C_1\text{-}C_6\text{-alkyl}$ or two radicals together form a $\text{-CH}_2\text{CH}_2\text{-}$ or
 $\text{-}(CH_3)_2\text{C-C(CH}_3)_2\text{-}$ bridge,


and

R^8 is $C_6\text{-}C_{10}\text{-aryl}$ or 5- to 10-membered heteroaryl which are optionally substituted by
radicals selected from the group of halogen, cyano, $C_1\text{-}C_6\text{-alkoxy}$, $C_1\text{-}C_6\text{-}$
alkoxycarbonyl, trifluoromethyl, 2,2,2-trifluoroethyl, trifluoromethoxy, $C_1\text{-}C_4\text{-alkyl}$
and $C_3\text{-}C_8\text{-cycloalkyl}$, where $C_1\text{-}C_4\text{-alkyl}$ is optionally substituted by hydroxy,

or a group of the formula



in an inert solvent in the presence of a base and of a transition metal catalyst to give
compounds of the formula



and the resulting compounds of the formula (IV), (VI) and (VIII) are optionally reacted with the appropriate (i) solvents and/or (ii) bases or acids to give the solvates, salts or solvates of the salts thereof.

5. (Cancelled).
6. (Currently amended) A medicament comprising at least one of the compounds as claimed in ~~any of claims claim 1 to 3~~ mixed together with at least one pharmaceutically acceptable, essentially nontoxic carrier or excipient.
7. (Currently amended) ~~The use of compounds as claimed in any of claims 1 to 3 for producing a medicament A method for the treatment and/or prophylaxis of central nervous system diseases comprising administering to a human or animal an effective amount of a compound of claim 1.~~
8. (Currently amended) ~~The use of compounds as claimed in any of claims 1 to 3 for producing a medicament A method for the treatment and/or prophylaxis of disorders of perception, concentration, learning and/or memory comprising administering to a human or animal an effective amount of a compound of claim 1.~~
9. (Currently amended) ~~The medicament as claimed in claim 6 A method for the treatment and/or prophylaxis of central nervous system diseases comprising administering to a human or animal an effective amount of a medicament of claim 6.~~

10. (Currently amended) ~~The medicament as claimed in claim 6~~ A method for the treatment and/or prophylaxis of disorders of perception, concentration, learning and/or memory diseases comprising administering to a human or animal an effective amount of a medicament of claim 6.
11. (Currently amended) A method for controlling disorders of perception, concentration, learning and/or memory in humans or animals by administering comprising administering to a human or animal an effective amount of the compounds from claims 1 to 3 a compound of claim 1.

New Claims (Attorney Docket No. LeA 35 926)

12. (New) The method of claim 4, wherein X is bromine.